The innate immune protein NLRP6, which plays a protective role in inflammatory bowel disease (IBD), appears to aggravate intestinal graft-vs.-host disease (GVHD).
SEATTLE – Clinical trial data for both approved and experimental HIV drugs were presented on the last day of the Conference on Retroviruses and Opportunistic Infections (CROI).
SEATTLE – Clinical trial data for both approved and experimental HIV drugs were presented on the last day of the Conference on Retroviruses and Opportunistic Infections (CROI).
Stimulator of interferon genes (STING) is an innate immune protein whose function is well described by its name. However, researchers at the University of Texas Southwestern Medical Center have discovered that STING also has a role in activating autophagy.
SEATTLE – The general public and HIV researchers alike were excited by the report out of the Conference on Retroviruses and Opportunistic Infections (CROI) this week that a second patient, the London patient, has been in long-term remission from HIV after receiving a bone marrow transplant with HIV-resistant cells to treat cancer.
SEATTLE –To hear National Institute of Allergy and Infectious Diseases Director Anthony Fauci tell it, ending the AIDS epidemic in the U.S. is another one of those things that took 20 years to become an overnight sensation.
SEATTLE – Ten years after "Berlin patient" Timothy Ray Brown, a second patient has achieved long-term undetectable viral load in the absence of antiretroviral treatment (ART) after receiving a bone marrow transplant with hematopoietic stem cells with a nonfunctional version of the CCR5 receptor, a surface molecule on helper T cells that is used as an entry co-receptor by HIV.
SEATTLE – Ten years after "Berlin patient" Timothy Ray Brown, a second patient has achieved long-term undetectable viral load in the absence of antiretroviral treatment (ART) after receiving a bone marrow transplant with hematopoietic stem cells with a nonfunctional version of the CCR5 receptor, a surface molecule on helper T cells that is used as an entry co-receptor by HIV.
Sleep is universal on both the species and the individual level. Though there have been reports of individuals, both in humans and other species, who need almost no sleep, a truly sleepless individual has never been identified.
Preventing off-target effects of CRISPR/Cas9 remains a major obstacle to the genome editing method's clinical application. In fact, even predicting when and where off-target effects will occur presently remains an imprecise undertaking at best. Researchers from Astrazeneca plc and Imperial College London have developed a molecular-precision tool for DNA manipulation that allowed them to demonstrate that CRISPR's off-target effects increased as DNA was physically stretched.
